Pramipexole or Ropinirole

Pramipexole and ropinirole are non-ergoline dopamine agonists primarily used to treat the symptoms of Parkinson's disease and restless legs syndrome. Both drugs work by stimulating dopamine receptors in the brain, mimicking the effects of the neurotransmitter dopamine, which is deficient in these conditions. Pramipexole was originally developed by Boehringer Ingelheim and Pharmacia and Upjohn, while ropinirole was originally developed by GlaxoSmithKline. They are administered orally and are available in both immediate-release and extended-release formulations. Both have been approved for medical use in the United States since 1997 (pramipexole) and 1997 (ropinirole) respectively, and are widely available as generic medications.

Brand names

MirapexMirapex ERSifrolPexolaMirapexinPipexusGleparkOprymeaAstepenCalmolanErimexolEzaprevFrodixGalipeksLabrixileMaripraxMedopexolMepimerMinergiMiparkanMiraperMivirenNuliparPactoPanarakParimParixolParkipexParkynParmitalPexa XRPeximyrPexoparPisaPortivPradosePramigenPramipexinPramirolPramithonPranowPrapexQuera LPRampiexRamixoleRapexoleRitmorestAxalanzBiopsolDerinikElderpatIntaxelMirapapkinMirapezolMovialMuvendNerviusNeurosomatNoxopranOxpolaPeriamidPralexanPramexolPramiferPramifrolPramiolaPramipPramitremPrimizolRamipexSimipexSimpralStabilTreminelTrimexolX-TrembleRequipRequip XLRepreveRonirolIpinniaRepinex

Other names

PramipexolPramipexolum(-)-PramipexoleU-98528EU98528EU 98528E(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamineNelipraxropinirole HClropinirole hydrochloride